Brain Cancer Clinical Trials in Los Angeles

Showing 81-100 of 183 trials

Oral ONC201 in Adult Recurrent Glioblastoma

NCT02525692

This was a Phase 2, open-label, 6-arm, multi-center study of dordaviprone (ONC201) in patients with recurrent glioblastoma (Arms A, B, and C), H3 K27M-mutant diffuse glioma (Arm D), or diffuse midline glioma (Arms E and F). The primary objective of this study was the assessment of dordaivprone (ONC201) anti-tumor activity through progression-free survival at 6 months using Response Assessment in Neuro-Oncology (RANO) criteria for high-grade glioma (HGG).

GlioblastomaDiffuse Midline GliomaH3 K27M Glioma+3 more

Jazz Pharmaceuticals84 participantsStarted Jan 2016

Los Angeles, California, United States • Miami, Florida, United States • Boston, Massachusetts, United States +2 more locations

COMPLETEDPhase 2< 1 mile

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

NCT03233204

This phase II Pediatric MATCH trial studies how well olaparib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with defects in deoxyribonucleic acid (DNA) damage repair genes that have spread to other places in the body (advanced) and have come back (relapsed) or do not respond to treatment (refractory). Olaparib is an inhibitor of PARP, an enzyme that helps repair DNA when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.

Advanced Malignant Solid NeoplasmAnn Arbor Stage III Childhood Non-Hodgkin LymphomaAnn Arbor Stage IV Childhood Non-Hodgkin Lymphoma+33 more

National Cancer Institute (NCI)6 participantsStarted Sep 2017

Birmingham, Alabama, United States • Anchorage, Alaska, United States • Mesa, Arizona, United States +110 more locations

Oral ONC201 in Adult Recurrent Glioblastoma

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Brain Cancer Trials in Other Cities

18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma

Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Dendritic Cell Vaccine for Patients With Brain Tumors

Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma

Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme

Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

Expanded Access Protocol Using 131I-MIBG

Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma

Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma

3D Prediction of Patient-Specific Response

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Other Conditions in Los Angeles